Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says

The dream to see arimoclomol approved as a Niemann-Pick type C treatment will not die with Orphazyme, should the firm be dissolved through a takeover, Deputy Chair Bo Jesper Hansen tells MedWatch.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

Embattled biotech firm Orphazyme announced last week that several potential buyers had made bids to buy all of the company’s assets and operations.

Orphazyme Deputy Chair Bo Jesper Hansen now tells MedWatch that the bids suggest potential buyers will continue chasing FDA approval of the firm’s lead asset, arimoclomol.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs